CELZ
NASDAQ · Biotechnology
Creative Medical Technology
$0.62
-0.01 (-2.07%)
Financial Highlights (FY 2026)
Revenue
16.5K
Net Income
-16,586,871
Gross Margin
63.5%
Profit Margin
-99,916.8%
Rev Growth
-59.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 63.5% | 63.5% | 46.2% | 46.2% |
| Operating Margin | -102,380.2% | -92,143.6% | -15.1% | -16.5% |
| Profit Margin | -99,916.8% | -94,921.0% | -20.6% | -17.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 16.5K | 40.6K | 749.0K | 753.7K |
| Gross Profit | 10.5K | 25.8K | 346.3K | 348.5K |
| Operating Income | -16,873,275 | -37,449,932 | -113,316 | -124,382 |
| Net Income | -16,586,871 | -36,814,263 | -154,552 | -129,649 |
| Gross Margin | 63.5% | 63.5% | 46.2% | 46.2% |
| Operating Margin | -102,380.2% | -92,143.6% | -15.1% | -16.5% |
| Profit Margin | -99,916.8% | -94,921.0% | -20.6% | -17.2% |
| Rev Growth | -59.5% | -59.5% | +1.8% | -1.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 572.6K | 615.2K |
| Total Equity | — | — | 3.37M | 3.00M |
| D/E Ratio | — | — | 0.17 | 0.21 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -16,654,115 | -39,017,038 | -155,667 | -163,320 |
| Free Cash Flow | — | — | -141,548 | -126,501 |